Piraeus Medical launches 6F 70 NeuGlide catheter in the U.S.

Piraeus Medical has launched the FDA-cleared 6F 70 NeuGlide Catheter in the U.S. and reported its first clinical cases. The device expands the company’s neurointerventional access lineup and is intended to help physicians navigate complex procedures through 6F access.

Why it matters: - The 6F 70 NeuGlide adds a new smaller-profile option to Piraeus Medical’s neurointerventional access portfolio. - The catheter is designed to balance inner diameter, outer diameter, distal flexibility and proximal support. - The launch targets complex neurovascular procedures where catheter access and positioning can affect clinical performance.

What happened: - Piraeus Medical announced the U.S. launch and first clinical cases of the 6F 70 NeuGlide Catheter on Sept. 18, 2026. - The launch followed FDA clearance. - The catheter joins the company’s existing 7F 87 NeuGlide+ and 8F 93 NeuFlex catheters.

The details: - The 6F 70 NeuGlide is built on Piraeus Medical’s patented linerless catheter construction. - The design is intended to optimize inner diameter relative to outer diameter. - The catheter combines distal flexibility with proximal support. - Piraeus Medical describes a three-platform access lineup across 6F, 7F and 8F sizes. - The company says the new catheter is part of its effort to rethink neurovascular access and give physicians more tools for increasingly complex procedures. - Dr. Brinjikji said the first-in-human case enabled distal positioning needed to successfully treat a complex dAVF through 6F access. - Piraeus Medical said the account from that case is genuine and documented, but does not guarantee similar results for other patients. - The company says the 70 NeuGlide Catheter is indicated for the introduction of interventional devices into the peripheral, coronary and neuro vasculature. - Those indications also apply to the 87 NeuGlide+ and 93 NeuFlex catheters. - Safety information and product labeling are available at More information.

Between the lines: - The launch signals Piraeus Medical is trying to compete on catheter design rather than just size range. - The first U.S. cases give the company an early clinical milestone, but the release offers only one physician account and no broader outcome data. - The emphasis on linerless construction suggests the company sees engineering as the main differentiator in a crowded access-device market.

What's next: - Piraeus Medical is likely to lean on early clinical use as it builds adoption for the 6F 70 NeuGlide. - Physicians and hospitals will look to product labeling and additional real-world cases before judging how the catheter performs across broader neurointerventional use. - The company’s customer service line is +1 507-782-0184 for follow-up questions.

The bottom line: - Piraeus Medical has taken its NeuroGlide platform to a new 6F tier, and the company is betting that a balance of support and flexibility will resonate in complex neurovascular cases.